Edition:
United Kingdom

BioLine RX Ltd (BLRX.OQ)

BLRX.OQ on NASDAQ Stock Exchange Capital Market

1.10USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$1.10
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
62,953
52-wk High
$1.38
52-wk Low
$0.80

Chart for

About

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in... (more)

Overall

No Ratios Available.

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-BioLineRx Reports Overall Survival Results From Long-term Follow-up of Phase 2a Trial in r/r AML

* BIOLINERX REPORTS OVERALL SURVIVAL RESULTS FROM LONG-TERM FOLLOW-UP OF PHASE 2A TRIAL IN R/R AML

04 Dec 2017

BRIEF-BioLine Rx Ltd Q3 ‍loss per ordinary share $0.07​

* BioLine Rx ltd - qtrly ‍loss per ordinary share $0.07​ Source text for Eikon: Further company coverage:

21 Nov 2017

BRIEF-BioLineRX initiates phase 1b/2 trial for BL-8040 in gastric cancer under immunotherapy collaboration

* BioLineRX announces initiation of phase 1b/2 trial for BL-8040 in gastric cancer under immunotherapy collaboration

18 Oct 2017

BRIEF-BioLineRx announces initiation of Phase 1b/2 trial for BL-8040 in AML under immunotherapy collaboration

* BioLineRx announces initiation of Phase 1b/2 trial for BL-8040 in AML under immunotherapy collaboration Source text for Eikon: Further company coverage:

26 Sep 2017

BRIEF-Biolinerx announces regulatory submission of phase 3 registrational study for BL-8040 in stem cell mobilization

* Biolinerx announces regulatory submission of phase 3 registrational study for bl-8040 in stem cell mobilization

21 Aug 2017

BRIEF-Biolinerx Q2 ‍loss per share $0.05​

* Qtrly ‍loss per share $0.05​ Source text for Eikon: Further company coverage:

08 Aug 2017

BRIEF-Biolinerx announces additional investment from BVF Partners L.P.

* BiolineRx announces additional investment from BVF partners L.P.

26 Jul 2017

BVF raises stake in biopharma firm BioLineRx to 24.9 pct

* Israeli biopharmaceutical firm BioLineRx said on Wednesday that BVF Partners, its largest shareholder, agreed to invest an additional $9.6 million in BioLineRx, raising its holding to 24.9 percent from 18.3 percent.

26 Jul 2017

Earnings vs. Estimates